Portal de Periódicos da CAPES

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

2014; Elsevier BV; Volume: 124; Issue: 23 Linguagem: Inglês

10.1182/blood-2014-04-531871

1528-0020

Julie Irving, Elizabeth Matheson, Lynne Minto, Helen J. Blair, Marian Case, Christina Halsey, Isabella Swidenbank, Frida Ponthan, Renate Kirschner‐Schwabe, Stefanie Groeneveld‐Krentz, Jana Hof, James M. Allan, Christine J. Harrison, Josef Vormoor, Arend von Stackelberg, Cornelia Eckert,

Acute Myeloid Leukemia Research

Key Points RAS pathway mutations are prevalent in relapsed childhood ALL, and KRAS mutations are associated with a poorer overall survival. RAS pathway mutations confer sensitivity to mitogen-activated protein kinase kinase inhibitors.